iLAC

iLAC is a private Japanese precision medicine and genomics company focused on disease diagnosis, biomarker discovery, and drug target discovery using high-throughput genome and multi-omics analysis. The company supports research in cancer, congenital metabolic disorders, intractable diseases, dementia, cardiovascular disease, and women's health, and also provides clinical research support for pharmaceutical development. Its capabilities span genome, transcriptome, epigenome, proteome, and metabolome analysis, combined with novel algorithm and AI-based analytics. iLAC appears to operate primarily as a precision diagnostics and research platform company rather than as a traditional therapeutic drug developer, with services and collaborations aimed at enabling personalized medicine and new target discovery.